Research and Development

Neovii continually invests in and partners with the medical and scientific research community, in order to expand into new areas and indications such as lung and pancreas transplants, paediatric, normothermic perfusion and autoimmune diseases including Type 1 Diabetes and Lupus Nephritis to name but a few.

With over 50 ongoing studies, educational and research initiatives currently being run globally, Neovii is proud to be at the forefront of academic and medical research, continuously working to improve the outcome for patients worldwide.

Expanded Access Program

Access to Investigational Drugs

The term expanded access is used to describe treatment with an investigational product for a patient with a serious or immediately life-threatening illness when there are no comparable or satisfactory alternative treatments available and the patient is ineligible or unable to participate in a clinical trial.

At the present Neovii does not offer an Expanded Access Program. However, Neovii continues to evaluate implementation of Expanded Access Program and will publish the Expanded Access Policy should it become available in the future.